Lixte Total Assets from 2010 to 2024

LIXTW Stock

USD 0.03 0.01 21.74%

Lixte Biotechnology Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 2.2 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2006-03-31

Previous Quarter

2.7 M

Current Value

1.7 M

Quarterly Volatility

2 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or EBITDA of 3.4 K, as well as many indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0011 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.

Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Total Assets Growth Pattern

Below is the plot of the Total Assets of Lixte Biotechnology Holdings over the last few years. Total assets refers to the total amount of Lixte Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lixte Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Lixte Biotechnology's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 4.31 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Lixte Total Assets Regression Statistics

	Arithmetic Mean	2,338,302
	Geometric Mean	1,127,258
	Coefficient Of Variation	86.87
	Mean Deviation	1,755,911
	Median	1,753,010
	Standard Deviation	2,031,305
	Sample Variance	4.1T
	Range	5.6M
	R-Value	0.77
	Mean Square Error	1.8T
	R-Squared	0.59
	Significance	0.0008
	Slope	349,550
	Total Sum of Squares	57.8T

Lixte Total Assets History

	2024	2.2 M
	2023	4.3 M
	2022	5.6 M
	2021	5.1 M
	2020	5.2 M
	2019	2.7 M
	2018	4.3 M

Other Fundumenentals of Lixte Biotechnology

Intangibles To Total Assets

Lixte Biotechnology Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Short Term Debt	Short Term Investments	Net Receivables	Current Deferred Revenue	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	-0.97	-0.76	0.24	1.0	-0.3	0.46	0.91	-0.11	-0.66	0.35	0.92	0.95	0.94	0.01
Total Stockholder Equity	0.96		-1.0	-0.84	0.21	0.96	-0.4	0.42	0.88	-0.14	-0.71	0.34	0.92	0.98	0.98	-0.27
Net Debt	-0.97	-1.0		0.83	-0.22	-0.97	0.38	-0.43	-0.89	0.17	0.72	-0.34	-0.92	-0.97	-0.97	0.23
Retained Earnings	-0.76	-0.84	0.83		-0.45	-0.75	0.38	-0.51	-0.72	0.08	0.71	-0.69	-0.87	-0.81	-0.82	0.43
Total Liab	0.24	0.21	-0.22	-0.45		0.24	0.13	0.66	0.25	0.33	-0.01	0.48	0.22	0.16	0.17	-0.06
Total Current Assets	1.0	0.96	-0.97	-0.75	0.24		-0.29	0.46	0.91	-0.11	-0.66	0.34	0.91	0.95	0.94	0.01
Common Stock	-0.3	-0.4	0.38	0.38	0.13	-0.29		0.16	-0.45	0.12	0.18	-0.21	-0.49	-0.45	-0.46	0.38
Accounts Payable	0.46	0.42	-0.43	-0.51	0.66	0.46	0.16		0.29	0.31	-0.54	0.29	0.39	0.41	0.4	-0.02
Short Term Debt	0.91	0.88	-0.89	-0.72	0.25	0.91	-0.45	0.29		-0.08	-0.53	0.47	0.9	0.9	0.89	-0.04
Short Term Investments	-0.11	-0.14	0.17	0.08	0.33	-0.11	0.12	0.31	-0.08		0.17	-0.06	-0.08	-0.08	-0.08	0.06
Net Receivables	-0.66	-0.71	0.72	0.71	-0.01	-0.66	0.18	-0.54	-0.53	0.17		-0.3	-0.72	-0.7	-0.7	0.22
Current Deferred Revenue	0.35	0.34	-0.34	-0.69	0.48	0.34	-0.21	0.29	0.47	-0.06	-0.3		0.51	0.35	0.35	-0.09
Capital Surpluse	0.92	0.92	-0.92	-0.87	0.22	0.91	-0.49	0.39	0.9	-0.08	-0.72	0.51		0.93	0.92	-0.13
Net Invested Capital	0.95	0.98	-0.97	-0.81	0.16	0.95	-0.45	0.41	0.9	-0.08	-0.7	0.35	0.93		1.0	-0.22
Net Working Capital	0.94	0.98	-0.97	-0.82	0.17	0.94	-0.46	0.4	0.89	-0.08	-0.7	0.35	0.92	1.0		-0.27
Capital Stock	0.01	-0.27	0.23	0.43	-0.06	0.01	0.38	-0.02	-0.04	0.06	0.22	-0.09	-0.13	-0.22	-0.27

Click cells to compare fundamentals

About Lixte Biotechnology Financial Statements

Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	4.3 M	2.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC